U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry RACEMIC
Molecular Formula C15H14N2O2
Molecular Weight 254.2839
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LICARBAZEPINE

SMILES

NC(=O)N1C2=CC=CC=C2C(O)CC3=C1C=CC=C3

InChI

InChIKey=BMPDWHIDQYTSHX-UHFFFAOYSA-N
InChI=1S/C15H14N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8,14,18H,9H2,(H2,16,19)

HIDE SMILES / InChI

Molecular Formula C15H14N2O2
Molecular Weight 254.2839
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Oxcarbazepine and its active metabolite (10,11-dihydro-10-hydroxy-carbazepine, MHD) have been effective in animal models of epilepsy that generally predict efficacy in generalized tonic-clonic seizures and partial seizures in humans. The pharmacokinetic profile of oxcarbazepine is less complicated than that of carbamazepine, with less metabolism by the cytochrome P450 system, no production of an epoxide metabolite, and lower plasma protein binding. The clinical efficacy and tolerability of oxcarbazepine have been demonstrated in trials in adults, children, and the elderly. The pharmacological activity of oxcarbazepine is primarily exerted through the 10-monohydroxy metabolite (MHD) of oxcarbazepine. The precise mechanism by which oxcarbazepine and MHD exert their antiseizure effect is unknown; however, in vitro electrophysiological studies indicate that they produce blockade of voltage-sensitive sodium channels, resulting in stabilization of hyperexcited neural membranes, inhibition of repetitive neuronal firing, and diminution of propagation of synaptic impulses. These actions are thought to be important in the prevention of seizure spread in the intact brain. In addition, increased potassium conductance and modulation of high-voltage activated calcium channels may contribute to the anticonvulsant effects of the drug.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
TRILEPTAL

Approved Use

Oxcarbazepine tablets are indicated for use as monotherapy or adjunctive therapy in the treatment of partial seizures in adults and as monotherapy in the treatment of partial seizures in children aged 4 years and above with epilepsy, and as adjunctive therapy in children aged 2 years and above with partial seizures. Oxcarbazepine tablet is an antiepileptic drug indicated for: Adults: -Monotherapy or adjunctive therapy in the treatment of partial seizures Children: -Monotherapy in the treatment of partial seizures in children 4-16 years -Adjunctive therapy in the treatment of partial seizures in children 2-16 years (1)

Launch Date

2000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
30.7 μM
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LICARBAZEPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
77.6 μM
500 mg 3 times / day steady-state, oral
dose: 500 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LICARBAZEPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
9349.83 ng/mL
600 mg single, oral
dose: 600 mg
route of administration: oral
experiment type: single
co-administered:
LICARBAZEPINE plasma
Homo sapiens
population:
age:
sex:
food status: Fed
3537.63 ng/mL
600 mg single, oral
dose: 600 mg
route of administration: oral
experiment type: single
co-administered:
OXCARBAZEPINE plasma
Homo sapiens
population:
age:
sex:
food status: Fed
7119 ng/mL
600 mg single, oral
dose: 600 mg
route of administration: oral
experiment type: single
co-administered:
LICARBAZEPINE plasma
Homo sapiens
population:
age:
sex:
food status: Fasted
1630.3 ng/mL
600 mg single, oral
dose: 600 mg
route of administration: oral
experiment type: single
co-administered:
OXCARBAZEPINE plasma
Homo sapiens
population:
age:
sex:
food status: Fasted
1.55 μg/mL
300 mg 2 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OXCARBAZEPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
503 μM × h
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LICARBAZEPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
747 μM × h
500 mg 3 times / day steady-state, oral
dose: 500 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LICARBAZEPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
197864.34 ng*h/mL
600 mg single, oral
dose: 600 mg
route of administration: oral
experiment type: single
co-administered:
LICARBAZEPINE plasma
Homo sapiens
population:
age:
sex:
food status: Fed
179002.4 ng*h/mL
600 mg single, oral
dose: 600 mg
route of administration: oral
experiment type: single
co-administered:
LICARBAZEPINE plasma
Homo sapiens
population:
age:
sex:
food status: Fed
9679.79 ng*h/mL
600 mg single, oral
dose: 600 mg
route of administration: oral
experiment type: single
co-administered:
OXCARBAZEPINE plasma
Homo sapiens
population:
age:
sex:
food status: Fed
9445.55 ng*h/mL
600 mg single, oral
dose: 600 mg
route of administration: oral
experiment type: single
co-administered:
OXCARBAZEPINE plasma
Homo sapiens
population:
age:
sex:
food status: Fed
173770 ng*h/mL
600 mg single, oral
dose: 600 mg
route of administration: oral
experiment type: single
co-administered:
LICARBAZEPINE plasma
Homo sapiens
population:
age:
sex:
food status: Fasted
157372 ng*h/mL
600 mg single, oral
dose: 600 mg
route of administration: oral
experiment type: single
co-administered:
LICARBAZEPINE plasma
Homo sapiens
population:
age:
sex:
food status: Fasted
5873.1 ng*h/mL
600 mg single, oral
dose: 600 mg
route of administration: oral
experiment type: single
co-administered:
OXCARBAZEPINE plasma
Homo sapiens
population:
age:
sex:
food status: Fasted
5309.5 ng*h/mL
600 mg single, oral
dose: 600 mg
route of administration: oral
experiment type: single
co-administered:
OXCARBAZEPINE plasma
Homo sapiens
population:
age:
sex:
food status: Fasted
3.76 μg × h/mL
300 mg 2 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OXCARBAZEPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
9.3 h
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LICARBAZEPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
11.3 h
500 mg 3 times / day steady-state, oral
dose: 500 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LICARBAZEPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
2.38 h
300 mg 2 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OXCARBAZEPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
70%
LICARBAZEPINE plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
27%
300 mg 2 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OXCARBAZEPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
8 mg/kg 1 times / day steady, oral
Recommended
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg/kg, 1 times / day
Sources:
unhealthy, 1 month -4 years
Health Status: unhealthy
Age Group: 1 month -4 years
Sources:
Disc. AE: Convulsions, Status epilepticus...
AEs leading to
discontinuation/dose reduction:
Convulsions (3.7%)
Status epilepticus (1.2%)
Ataxia (1.2%)
Sources:
15 g single, oral
Overdose
Dose: 15 g
Route: oral
Route: single
Dose: 15 g
Sources:
unhealthy, 13 years
Health Status: unhealthy
Age Group: 13 years
Sex: M
Sources:
Other AEs: Vomiting...
Other AEs:
Vomiting (1 patient)
Sources:
2700 mg 1 times / day multiple, oral
Highest studied dose
Dose: 2700 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2700 mg, 1 times / day
Sources:
unhealthy, 19-70 years
Health Status: unhealthy
Age Group: 19-70 years
Sex: M+F
Sources:
Other AEs: Dizziness, Tremor...
Other AEs:
Dizziness
Tremor
Somnolence
Headache
Sources:
30600 mg single, oral
Overdose
Dose: 30600 mg
Route: oral
Route: single
Dose: 30600 mg
Sources:
unhealthy, 36 years
Health Status: unhealthy
Age Group: 36 years
Sex: M
Sources:
8 mg/kg 1 times / day steady, oral
Recommended
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg/kg, 1 times / day
Sources:
unhealthy, 4-16 years
Health Status: unhealthy
Age Group: 4-16 years
Sources:
Disc. AE: Somnolence, Vomiting...
AEs leading to
discontinuation/dose reduction:
Somnolence (2.4%)
Vomiting (2%)
Ataxia (1.8%)
Diplopia (1.3%)
Dizziness (1.3%)
Fatigue (1.1%)
Nystagmus (1.1%)
Sources:
12 mg/kg 1 times / day steady, oral
Dose: 12 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 12 mg/kg, 1 times / day
Sources:
unhealthy, 6 years
Health Status: unhealthy
Age Group: 6 years
Sex: M
Sources:
Disc. AE: Stevens Johnson syndrome...
AEs leading to
discontinuation/dose reduction:
Stevens Johnson syndrome (1 patient)
Sources:
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
Disc. AE: Hyponatremia...
AEs leading to
discontinuation/dose reduction:
Hyponatremia (2.5%)
Sources:
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
Disc. AE: Dizziness, Diplopia...
AEs leading to
discontinuation/dose reduction:
Dizziness (6.4%)
Diplopia (5.9%)
Ataxia (5.2%)
Vomiting (5.1%)
Nausea (4.9%)
Somnolence (3.8%)
Headache (2.9%)
Fatigue (2.1%)
Abnormal vision (2.1%)
Tremor (1.8%)
Abnormal gait (1.7%)
Rash (1.4%)
Hyponatremia (1%)
Sources:
500 mg 2 times / day multiple, oral
Studied dose
Dose: 500 mg, 2 times / day
Route: oral
Route: multiple
Dose: 500 mg, 2 times / day
Sources:
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Sources:
AEs

AEs

AESignificanceDosePopulation
Ataxia 1.2%
Disc. AE
8 mg/kg 1 times / day steady, oral
Recommended
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg/kg, 1 times / day
Sources:
unhealthy, 1 month -4 years
Health Status: unhealthy
Age Group: 1 month -4 years
Sources:
Status epilepticus 1.2%
Disc. AE
8 mg/kg 1 times / day steady, oral
Recommended
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg/kg, 1 times / day
Sources:
unhealthy, 1 month -4 years
Health Status: unhealthy
Age Group: 1 month -4 years
Sources:
Convulsions 3.7%
Disc. AE
8 mg/kg 1 times / day steady, oral
Recommended
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg/kg, 1 times / day
Sources:
unhealthy, 1 month -4 years
Health Status: unhealthy
Age Group: 1 month -4 years
Sources:
Vomiting 1 patient
15 g single, oral
Overdose
Dose: 15 g
Route: oral
Route: single
Dose: 15 g
Sources:
unhealthy, 13 years
Health Status: unhealthy
Age Group: 13 years
Sex: M
Sources:
Dizziness
2700 mg 1 times / day multiple, oral
Highest studied dose
Dose: 2700 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2700 mg, 1 times / day
Sources:
unhealthy, 19-70 years
Health Status: unhealthy
Age Group: 19-70 years
Sex: M+F
Sources:
Headache
2700 mg 1 times / day multiple, oral
Highest studied dose
Dose: 2700 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2700 mg, 1 times / day
Sources:
unhealthy, 19-70 years
Health Status: unhealthy
Age Group: 19-70 years
Sex: M+F
Sources:
Somnolence
2700 mg 1 times / day multiple, oral
Highest studied dose
Dose: 2700 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2700 mg, 1 times / day
Sources:
unhealthy, 19-70 years
Health Status: unhealthy
Age Group: 19-70 years
Sex: M+F
Sources:
Tremor
2700 mg 1 times / day multiple, oral
Highest studied dose
Dose: 2700 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2700 mg, 1 times / day
Sources:
unhealthy, 19-70 years
Health Status: unhealthy
Age Group: 19-70 years
Sex: M+F
Sources:
Fatigue 1.1%
Disc. AE
8 mg/kg 1 times / day steady, oral
Recommended
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg/kg, 1 times / day
Sources:
unhealthy, 4-16 years
Health Status: unhealthy
Age Group: 4-16 years
Sources:
Nystagmus 1.1%
Disc. AE
8 mg/kg 1 times / day steady, oral
Recommended
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg/kg, 1 times / day
Sources:
unhealthy, 4-16 years
Health Status: unhealthy
Age Group: 4-16 years
Sources:
Diplopia 1.3%
Disc. AE
8 mg/kg 1 times / day steady, oral
Recommended
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg/kg, 1 times / day
Sources:
unhealthy, 4-16 years
Health Status: unhealthy
Age Group: 4-16 years
Sources:
Dizziness 1.3%
Disc. AE
8 mg/kg 1 times / day steady, oral
Recommended
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg/kg, 1 times / day
Sources:
unhealthy, 4-16 years
Health Status: unhealthy
Age Group: 4-16 years
Sources:
Ataxia 1.8%
Disc. AE
8 mg/kg 1 times / day steady, oral
Recommended
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg/kg, 1 times / day
Sources:
unhealthy, 4-16 years
Health Status: unhealthy
Age Group: 4-16 years
Sources:
Vomiting 2%
Disc. AE
8 mg/kg 1 times / day steady, oral
Recommended
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg/kg, 1 times / day
Sources:
unhealthy, 4-16 years
Health Status: unhealthy
Age Group: 4-16 years
Sources:
Somnolence 2.4%
Disc. AE
8 mg/kg 1 times / day steady, oral
Recommended
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg/kg, 1 times / day
Sources:
unhealthy, 4-16 years
Health Status: unhealthy
Age Group: 4-16 years
Sources:
Stevens Johnson syndrome 1 patient
Disc. AE
12 mg/kg 1 times / day steady, oral
Dose: 12 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 12 mg/kg, 1 times / day
Sources:
unhealthy, 6 years
Health Status: unhealthy
Age Group: 6 years
Sex: M
Sources:
Hyponatremia 2.5%
Disc. AE
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
Hyponatremia 1%
Disc. AE
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
Rash 1.4%
Disc. AE
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
Abnormal gait 1.7%
Disc. AE
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
Tremor 1.8%
Disc. AE
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
Abnormal vision 2.1%
Disc. AE
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
Fatigue 2.1%
Disc. AE
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
Headache 2.9%
Disc. AE
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
Somnolence 3.8%
Disc. AE
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
Nausea 4.9%
Disc. AE
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
Vomiting 5.1%
Disc. AE
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
Ataxia 5.2%
Disc. AE
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
Diplopia 5.9%
Disc. AE
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
Dizziness 6.4%
Disc. AE
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
inconclusive [Activation 39.8107 uM]
likely
no [IC50 >133 uM]
no [IC50 >133 uM]
no [IC50 >133 uM]
no [IC50 >133 uM]
no [Ki 1150 uM]
no [Ki >1350 uM]
no [Ki >1350 uM]
no [Ki >1350 uM]
no [Ki >1350 uM]
no [Ki >1350 uM]
no [Ki >1350 uM]
no [Ki >1350 uM]
no [Ki >1800 uM]
no [Ki >1800 uM]
no [Ki >900 uM]
no [Ki >900 uM]
weak [Ki 270 uM]
weak [Ki 647 uM]
weak
yes [Ki 228 uM]
yes [Ki 88 uM]
yes
yes
yes
yes
yes (co-administration study)
Comment: Coadministration of OXCARBAZEPINE decreased the AUC for Felodipine and Ethinylestradiol (both CYP3A4 substrate)
Page: (Pharm) 19, (Label) 18
Drug as victim
PubMed

PubMed

TitleDatePubMed
[New antiepileptic drugs in childhood epilepsies: indications and limits].
2001
Concerns with antiepileptic drug initiation: safety, tolerability, and efficacy.
2001
Behavioural effects of the new anticonvulsants.
2001
Effects of antiepileptic drugs on cognition.
2001
Second generation anticonvulsant medications: their use in children.
2001 Apr
Oxcarbazepine in the treatment of epilepsy.
2001 Aug
Newer antiepileptic drugs: advantages and disadvantages.
2001 Aug
Clinical pharmacology and therapeutic use of the new antiepileptic drugs.
2001 Dec
The role of new antiepileptic drugs.
2001 Jul
Pharmacologic management of epilepsy in the elderly.
2001 May-Jun
Symptomatic trigeminal-autonomic cephalalgia evolving to trigeminal neuralgia: report of a case associated with dual pathology.
2001 Nov
Review of treatment options for refractory epilepsy: new medications and vagal nerve stimulation.
2001 Nov
Infantile spasms: diagnosis and assessment of treatment response by video-EEG.
2001 Oct
Plasma concentration of topiramate correlates with cerebrospinal fluid concentration.
2001 Oct
Oxcarbazepine in bipolar disorder.
2001 Sep
Recommendations on the clinical use of oxcarbazepine in the treatment of epilepsy: a consensus view.
2001 Sep
Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review.
2001 Sep
Oxcarbazepine (Trileptal) as monotherapy in patients with partial seizures.
2001 Sep 11
Interactions between antiepileptic drugs and hormonal contraception.
2002
Effect of antiepileptic drugs on cognitive function in individuals with epilepsy: a comparative review of newer versus older agents.
2002
Anticonvulsants: aspects of their mechanisms of action.
2002
Oxcarbazepine and hepatic porphyria.
2002 Apr
Oxcarbazepine-induced syndrome of inappropriate secretion of antidiuretic hormone.
2002 Aug
New antiepileptic drugs: review on drug interactions.
2002 Feb
Marketed new antiepileptic drugs: are they better than old-generation agents?
2002 Feb
Pediatric partial and generalized seizures.
2002 Jan
Gateways to clinical trials.
2002 Jul-Aug
Gateways to Clinical Trials. June 2002.
2002 Jun
Some common issues in the use of antiepileptic drugs.
2002 Mar
[New antiepileptic drugs: new therapeutic options].
2002 May
Octakis-6-sulfato-gamma-cyclodextrin as additive for capillary electrokinetic chromatography of dibenzoazepines: carbamazepine, oxcarbamazepine and their metabolites.
2002 Sep
Use of anticonvulsants for treatment of neuropathic pain.
2002 Sep 10
Antiepileptic drug use during the first 12 months of vagus nerve stimulation therapy: a registry study.
2002 Sep 24
Binding of licarbazepine enantiomers to mouse and human plasma proteins.
2010 Jul
Development and validation of an HPLC-UV method for the simultaneous quantification of carbamazepine, oxcarbazepine, eslicarbazepine acetate and their main metabolites in human plasma.
2010 Jun
Patents

Sample Use Guides

Bipolar I Disorder: 750- 2000 mg/day
Route of Administration: Oral
Free and bound fractions of S-licarbazepine (S-Lic) and R-licarbazepine (R-Lic) were separated by ultrafiltration after previous in vitro incubation of spiked plasma samples and protein solutions with each enantiomer at 10, 25 and 50 ug/ml.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:13:30 GMT 2025
Edited
by admin
on Mon Mar 31 18:13:30 GMT 2025
Record UNII
XFX1A5KJ3V
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LICARBAZEPINE
INN   WHO-DD  
INN  
Official Name English
Licarbazepine [WHO-DD]
Preferred Name English
licarbazepine [INN]
Common Name English
10,11-DIHYDRO-10-HYDROXY-5H-DIBENZ(B,F)AZEPINE-5-CARBOXAMIDE
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C264
Created by admin on Mon Mar 31 18:13:30 GMT 2025 , Edited by admin on Mon Mar 31 18:13:30 GMT 2025
Code System Code Type Description
INN
7788
Created by admin on Mon Mar 31 18:13:30 GMT 2025 , Edited by admin on Mon Mar 31 18:13:30 GMT 2025
PRIMARY
CAS
29331-92-8
Created by admin on Mon Mar 31 18:13:30 GMT 2025 , Edited by admin on Mon Mar 31 18:13:30 GMT 2025
PRIMARY
EPA CompTox
DTXSID50865484
Created by admin on Mon Mar 31 18:13:30 GMT 2025 , Edited by admin on Mon Mar 31 18:13:30 GMT 2025
PRIMARY
NCI_THESAURUS
C81475
Created by admin on Mon Mar 31 18:13:30 GMT 2025 , Edited by admin on Mon Mar 31 18:13:30 GMT 2025
PRIMARY
ChEMBL
CHEMBL1067
Created by admin on Mon Mar 31 18:13:30 GMT 2025 , Edited by admin on Mon Mar 31 18:13:30 GMT 2025
PRIMARY
WIKIPEDIA
Licarbazepine
Created by admin on Mon Mar 31 18:13:30 GMT 2025 , Edited by admin on Mon Mar 31 18:13:30 GMT 2025
PRIMARY
SMS_ID
100000126209
Created by admin on Mon Mar 31 18:13:30 GMT 2025 , Edited by admin on Mon Mar 31 18:13:30 GMT 2025
PRIMARY
EVMPD
SUB32907
Created by admin on Mon Mar 31 18:13:30 GMT 2025 , Edited by admin on Mon Mar 31 18:13:30 GMT 2025
PRIMARY
FDA UNII
XFX1A5KJ3V
Created by admin on Mon Mar 31 18:13:30 GMT 2025 , Edited by admin on Mon Mar 31 18:13:30 GMT 2025
PRIMARY
CHEBI
701
Created by admin on Mon Mar 31 18:13:30 GMT 2025 , Edited by admin on Mon Mar 31 18:13:30 GMT 2025
PRIMARY
PUBCHEM
114709
Created by admin on Mon Mar 31 18:13:30 GMT 2025 , Edited by admin on Mon Mar 31 18:13:30 GMT 2025
PRIMARY
Related Record Type Details
BINDER->LIGAND
Related Record Type Details
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
ACTIVE MOIETY